Therapeutic simplification with lamivudine and dolutegravir in patients living with HIV in Ceará (LAMDO study)
DOI:
https://doi.org/10.33448/rsd-v11i9.32251Keywords:
Antiretrovirals; Simplification; Human immunodeficiency virus; Viral load; Dolutegravir.Abstract
The Ministry of Health approved dual therapy (lamivudine associated with a second antiretroviral) as a therapeutic option in the contraindication to the use of other available Nucleoside Analog Reverse Transcriptase Inhibitors - NRTIs (tenofovir, abacavir and zidovudine) due to toxicity, if patients are virological suppression. This study aims to evaluate the effectiveness of therapeutic simplification with lamivudine/dolutegravir (3TC/DTG) in HIV patients on antiretroviral therapy (ART). Retrospective study of the real-life experience in the clinical practice of a simplified scheme with 3TC/DTG in a referral hospital for infectious diseases. We evaluated 76 patients using 3TC/DTG, with a mean age of 56.4 years, 50 (65.8%) of whom were male, mean use of the simplified regimen of 12 months, mean CD4 count = 669.5 cells/ mm3 and average CD8 = 941.5 cells/mm3. Evaluation of viral load after simplification in 67 patients, 63 (94.0%) with maintained virological suppression (<40 copies) and 4 (6.0%) with detected viral load. Among these patients without complete virological suppression, two reported good adherence and the other two described poor adherence in the medical records. The current study confirms the effectiveness of virological suppression in real-life therapeutic simplification with 3TC/DTG. Therapeutic simplification with this regimen is a safe strategy as an option for patients with toxicity or intolerance to regimens containing NRTIs. Long-term studies are needed to confirm the maintenance of efficacy for longer periods of time.
References
Barker, G. (2008). Saúde Do Adolescente: Competências E Habilidades. Ministério da Saúde. 223-230. https://bvsms.saude.gov.br/bvs/publicacoes/saude_adolescente_competencias_habilidades.pdf
Bernardes, I. A. S., Araújo, J. A. de, Cortez, E. N., Oliveira, M. M., Ferreira, M. A., Fonseca, D. F. da, & Andrade, H. S. (2021). Interações medicamentosas entre pacientes com HIV/AIDS. Research, Society and Development, 10 (15). https://rsdjournal.org/index.php/rsd/article/view/22838
Boffito, M., Waters, L., Cahn, P., Paredes, R., Koteff, J., Wyk, J. V., Vincent, T., Demarest, J., Adkison, K., & Quercia, R. (2020). Perspectives On The Barrier To Resistance For Dolutegravir + Lamivudine, A Two-Drug Antiretroviral Therapy For Hiv-1 Infection. Aids Research And Human Retroviruses, 36 (1), 13-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944139/
Borghetti, A., Lombardi, F., Gagliardini, R., Baldin, G., Cicullo, A., Moschese, D., Emiliozzi, A., Belmonti, S., Lamonica, S., Montagnani, F., Visconti, E., De Luca, A., & Di Giambenedetto, S. (2019). Eficácia e tolerabilidade da lamivudina mais dolutegravir em comparação com lamivudina mais IPs em indivíduos HIV-1 positivos com supressão virológica: um estudo retrospectivo da prática clínica. BMC Infect Dis. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3666-8
Brasil (2008). Pesquisa de conhecimentos, atitudes e práticas na população brasileira. Ministério da Saúde. https://bvsms.saude.gov.br/bvs/publicacoes/pesquisa_conhecimentos_atitudes_praticas_populacao_brasileira.pdf
Brasil (2018). Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Ministério da Saúde. http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos
Brasil (2020). Boletim Epidemiológico Especial. Ministério da Saúde. http://www.aids.gov.br/pt-br/pub/2020/boletim-epidemiologico-hivaids-2020
Brasil (2020). Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis (IST). Ministério da Saúde. http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-atencao-integral-pessoas-com-infeccoes
Brites, C. (2016). Estratégias De Troca (Switch) Na Terapia Antirretroviral Atual. Bjid: Educação médica continuada, 2 (1), 24-32. https://www.bjid.org.br/en-estrategias-troca-switch-na-terapia-articulo-X2177511716525069
Cahn, P., Rólon, M. J., Figueroa, M. I., Gun, A., Patterson, P., & Sued, O. (2017). Dolutegravir-Lamivudine As Initial Therapy In Hiv-1 Infected, Arv-Naive Patients, 48-Week Results Of The Paddle (Pilot Antiretroviral Design With Dolutegravir Lamivudine) Study. J Int Aids Soc, 20 (1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515053/
Cavalcanti, A (2005). Dissertação de Mestrado em Medicina Tropical. Universidade Federal de Pernambuco, Recife.
Cento, V., & Perno, C. F. (2020). Two-Drug Regimens With Dolutegravir Plus Rilpivirine Or Lamivudine Inhiv-1 Treatment-Naïve, Virologically-Suppressed Patients: Latestevidence From The Literature On Their Efficacy And Safet. Journal Of Global Antimicrobial Resistance, 20, 228–237. https://www.sciencedirect.com/science/article/pii/S2213716519302085?via%3Dihub
Cesar, C., Shepherd, B. E., Krolewiecki, A. J., Fink, V. I., Schetter, M., Tuboi, S. H., Wolff, M., Pape, J. W., Leger, P., Padgett, D., Madero, J. S., Gotuzzo, E., & Sued, O. (2010). Rates And Reasons For Early Change Of First Haart In Hiv-1-Infected Patients In 7 Sites Throughout The Caribbean And Latin America. Plos One, 5 (6). https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010490
Ciccullo, A., Baldin, G., Borghetti, A., & Di Giambenedetto, S. (2020). Dolutegravir Plus Lamivudine For The Treatment Of Hiv-1 Infection. Expert Review Of Anti-Infective Therapy, 1-14. https://www.tandfonline.com/doi/abs/10.1080/14787210.2020.1729742?journalCode=ierz20
Hastain, N. V., Santana, A., & Schafer, J. (2020). The Incidence And Severity Of Drug Interactions Before And After Antiretroviral Therapy Simplification In Treatment-Experienced Patients With Hiv Infection. Annals Of Pharmacotherapy, 54 (1), 36-42. https://journals.sagepub.com/doi/10.1177/1060028019867970?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&
Hidalgo-Tenorio, C., Cortés, L. L., Gutiérrez, A., Santos, J., Omar, M., Gálvez, C., Sequera, S., De Jesús, S. E., Téllez, F., Fernández, E., García, C., & Pasquau, J. (2019). Estudo DOLAMA. Medicine, 98 (32), 1-7. Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708975/
Joly, V., Burdet, C., Landman, R., Vigan, M., Charpentier, C., Katlama, C., Cabié, A., Benalycherif, A., Peytavin, G., Yeni, P., Mentre, F., Argoud, A., Amri, I., Descamps, D., & Yazdanpanah, Y. (2019). Dolutegravir And Lamivudine Maintenance Therapy In Hiv-1 Virologically Suppressed Patients: Results Of The Anrs 167 Trial (Lamidol). Journal Of Antimicrobial Chemotherapy, 74 (3), 739-745. Https://academic.oup.com/jac/article/74/3/739/5203400
Kumarasamy, N., Patel, A., & Pujari, S. (2011). Antiretroviral Therapy In Indian Setting: When & What To Start With, When & What To Switch To? The Indian Journal Of Medical Research, 134 (6), 787-800. Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284090/
Lombardi, F., Belmonti, S., Borghetti, A., Fabbiani, M., Marchetti, S., Tamburrini, E., Cauda, R., & Di Giambenedetto, S. (2020). Evolution Of Cellular Hiv Dna Levels In Virologically Suppressed Patients Switching To Dolutegravir/Lamivudine Versus Maintaining A Triple Regimen: A Prospective, Longitudinal, Matched, Controlled Study. Journal Of Antimicrobial Chemotherapy. Https://academic.oup.com/jac/article/75/6/1599/5760356
Mendonça, E., Araújo, E. da C., Botelho, E. P., Polaro, S. H. I., & Gonçalves, L. H. T. (2020). Experiência de sexualidade e HIV/Aids na terceira idade. Research, Society and Development, 9 (7). https://rsdjournal.org/index.php/rsd/article/view/4256
Oliveira, E., Rufino, J. L. N., Verde, R. M. C. L., Soares, L. F., Cabral, L. de O., & Vallinoto, A. C. R. (2020). Caracterização epidemiológica de indivíduos com vírus da imunodeficiência humana-1 no estado do Piauí, Brasil. Research, Society and Development, 9 (2). https://rsdjournal.org/index.php/rsd/article/view/2002
Oliveira, M., Junior, V. R. de S., Vidal, C. F de L., & Araújo, P. S R. de. (2018). Virologic Suppression In Response To Antiretroviral Therapy Despite Extensive Resistance Within Hiv-1 Reverse Transcriptase After The First Virologic Failure. Bmc Infectious Diseases, 514 (18), 1-11. Https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3400-6
Osorio T., Rivera, L. C., Pino-Marín, M., Esteban, D., Andrés, G. N., & Amariles, P. (2019). Relevancia clínica de lasinteracciones medicamentosas en pacientes infectados con el virus de la inmunodeficiencia humana: actualización 2015-2017. Revista chilena de infectología, 36 (4), 475-489. https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182019000400475
Ranganathan, P., & Aggarwal, R. (2018). Study designs: Part 1 - An overview and classification. Perspectives in clinical research, 9(4), 184–186. https://doi.org/10.4103/picr.PICR_124_18
Setia M. S. (2016). Methodology Series Module 3: Cross-sectional Studies. Indian journal of dermatology, 61(3), 261–264. https://doi.org/10.4103/0019-5154.182410
Smit, M., Brinkman, K., Geerlings, S., Smit, C., Thyagarajan, K., Sighem, A., Wolf, F. de., & Hallett, T. B. (2015). Future challenges for clinical care of an ageing population infected with HIV: a modelling study. The Lancet Infectious Diseases, 15 (7), 810-818. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528076/
Soriano, V., Fernández-Montero, J. V., Benitez-Gutierrez, L., Mendonza, C. de., Árias, A., Barreiro, P., Pena, J. M., & Labarga, P. (2017). Dual antiretroviral therapy for HIV infection. Expert Opinion On Drug Safety, 16 (8), 923-932. Https://www.tandfonline.com/doi/abs/10.1080/14740338.2017.1343300?journalCode=ieds20
UNAIDS (2020). Joint United Nations Programme on HIV/AIDS. Statistics. Geneva: UNAIDS. https://unaids.org.br/estatisticas/
Zamora, F. J., Dowers, E., Yasin, F., & Ogbuagu, O. (2019). Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection. Hiv/aids - Research And Palliative Care, 11, 255-263. Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817767/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Melina Maria Loiola Melo Vasconcelos ; Erico Antonio Gomes Arruda; Amanda Pinheiro Ibiapina ; Lara Farias Lustosa da Costa; Ana Luiza Maria Viana de Araújo ; Melissa Soares Medeiros
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
